The bioequivalence study of Capecitabine in Patients with Breast or Colorectal Cancer under Fed condition

ABSTRACT: Intervention1: Capecitabine: 1250 mg/m2 oral twice a day for one day Control Intervention1: Xeloda: 1250 mg/m2 oral twice a day for two days Primary outcome(s): Pharmacokinetic parameters: Cmax and AUC0-t of capecitabine in plasma.Timepoint: 0.250, 0.500, 1.000, 1.500 Study Design: Randomized, Crossover Trial Method of generating randomization sequence:Other Method of allocation concealment:Other Blinding and masking:Open Label

DISEASE(S): Malignant Neoplasm Of Colon, Unspecified

PROVIDER: 2575050 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR